Additionally, the inactivation of the PERK-elF2a-phosphorylation arm has been shown to sensitize CD34 + BP CML cells to imatinib-induced cell death [25]. This evidence concerns the gene EIF2AK3 and chronic myelogenous leukemia, BCR-ABL1 positive.